Roflumilast foam (Zoryve) for seborrheic dermatitis
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:66 |
|---|---|
| Enthalten in: |
The Medical letter on drugs and therapeutics - 66(2024), 1700 vom: 15. Apr., Seite 57-59 |
| Sprache: |
Englisch |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 08.04.2024 Date Revised 08.04.2024 published: Print Citation Status MEDLINE |
|---|
| doi: |
10.58347/tml.2024.1700a |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370655672 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370655672 | ||
| 003 | DE-627 | ||
| 005 | 20240408233040.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240405s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.58347/tml.2024.1700a |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1369.xml |
| 035 | |a (DE-627)NLM370655672 | ||
| 035 | |a (NLM)38576147 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 245 | 1 | 0 | |a Roflumilast foam (Zoryve) for seborrheic dermatitis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 08.04.2024 | ||
| 500 | |a Date Revised 08.04.2024 | ||
| 500 | |a published: Print | ||
| 500 | |a Citation Status MEDLINE | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Daliresp | |
| 650 | 4 | |a Elidel | |
| 650 | 4 | |a Protopic | |
| 650 | 4 | |a Zoryve | |
| 650 | 4 | |a adverse effects | |
| 650 | 4 | |a antifungals | |
| 650 | 4 | |a betamethasone | |
| 650 | 4 | |a ciclopirox | |
| 650 | 4 | |a corticosteroids | |
| 650 | 4 | |a dosage | |
| 650 | 4 | |a drug interactions | |
| 650 | 4 | |a efficacy | |
| 650 | 4 | |a hydrocortisone | |
| 650 | 4 | |a ketoconazole | |
| 650 | 4 | |a lactation | |
| 650 | 4 | |a pimecrolimus | |
| 650 | 4 | |a pregnancy | |
| 650 | 4 | |a roflumilast | |
| 650 | 4 | |a safety | |
| 650 | 4 | |a seborrheic dermatitis | |
| 650 | 4 | |a sulfacetamide | |
| 650 | 4 | |a tacrolimus | |
| 650 | 7 | |a Roflumilast |2 NLM | |
| 650 | 7 | |a 0P6C6ZOP5U |2 NLM | |
| 650 | 7 | |a Aminopyridines |2 NLM | |
| 650 | 7 | |a Benzamides |2 NLM | |
| 650 | 7 | |a Cyclopropanes |2 NLM | |
| 650 | 7 | |a Dermatologic Agents |2 NLM | |
| 773 | 0 | 8 | |i Enthalten in |t The Medical letter on drugs and therapeutics |d 1965 |g 66(2024), 1700 vom: 15. Apr., Seite 57-59 |w (DE-627)NLM000074810 |x 1523-2859 |7 nnns |
| 773 | 1 | 8 | |g volume:66 |g year:2024 |g number:1700 |g day:15 |g month:04 |g pages:57-59 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.58347/tml.2024.1700a |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 66 |j 2024 |e 1700 |b 15 |c 04 |h 57-59 | ||